Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development
Go back to Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 0.78 +0.01 (1.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.77 | 52 Week High | $9.58 | |||
| Open | $0.79 | 52 Week Low | $2.34 | |||
| Day High | $0.79 | P/E | N/A | |||
| Day Low | $0.77 | EPS | $-0.34 | |||
| Volume | 55,766 | |||||
